Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Foghorn Therapeutics Inc. | d105868dex322.htm |
| EX-32.1 - EX-32.1 - Foghorn Therapeutics Inc. | d105868dex321.htm |
| EX-31.2 - EX-31.2 - Foghorn Therapeutics Inc. | d105868dex312.htm |
| EX-31.1 - EX-31.1 - Foghorn Therapeutics Inc. | d105868dex311.htm |
| EX-10.18 - EX-10.18 - Foghorn Therapeutics Inc. | d105868dex1018.htm |
| EX-4.6 - EX-4.6 - Foghorn Therapeutics Inc. | d105868dex46.htm |
| 10-K - 10-K - Foghorn Therapeutics Inc. | d105868d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-252119 on Form S-8 of our report dated March 18, 2021, relating to the consolidated financial statements of Foghorn Therapeutics Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 18, 2021